Associate Professor, Medicine, Indiana University School of Medicine
Oncology
Dr. Bryan P. Schneider, MD
|
|
Give Review
Bryan Schneider practices Oncology. He researched medicine at Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He over the years received 8 awards: "Forty under 40", "Young Investigator Award", "Selected to be highlighted in the Best of ASCO Program", "Early Career Achievement Award", "Susan G. Komen for the Cure: Lifetime Achievement Award", "Career Development Award", "Paul Carbone, MD Fellowship Award" and "Merit Award". Bryan Schneider is also published. He has 39 publications published. The lastest publication: "A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.' Bryan Schneider accepts Medicare payments and is listed with Medicare.gov.
Publications
- A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.
- Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy.
- Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
- Incremental Prognostic Value of Echocardiographic Strain and Its Association With Mortality in Cancer Patients.
- Integrated and convenient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for LC-MS/MS Analysis.
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
- Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer.
- Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast Cancer participating in E5103.
- Characterizing the heterogeneity of triple-negative breast Cancers using microdissected normal ductal epithelium and RNA-sequencing.
- Survival in patients with metastatic recurrent breast Cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years.
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bev...
- Functional microRNAs in Alzheimer's disease and Cancer: differential regulation of common mechanisms and pathway.
- Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment.
- Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial.
- Advanced cognitive training for breast Cancer survivors: a randomized controlled trial.
- Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer.
- Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability.
- Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide.
- Anti-Vascular Endothelial Growth Factor Therapy for Breast Cancer: Can We Pick the Winners?
- Compliance differences between patients with breast Cancer in university and county hospitals.
- The role of vascular endothelial growth factor genetic variability in Cancer.
- Triple-negative breast Cancer: risk factors to potential targets.
- Is the blood-Brain barrier relevant in metastatic germ cell tumor?
- Angiogenesis of breast Cancer.
- Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell Cancer.
- Phase II study of gemcitabine plus docetaxel in advanced pancreatic Cancer: a Hoosier Oncology Group study.
- Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity.
- Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
- Association of polymorphisms of angiogenesis genes with breast Cancer.
- A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell Tumors.
- Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes.
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compare...
- Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes.
- Drug insight: VEGF as a therapeutic target for breast Cancer.
- A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.
- Altered cerebral blood flow one month after systemic chemotherapy for breast Cancer: a prospective study using pulsed arterial spin labeling MRI perfusion.
Schools
Indiana University School Of Medicine
In University School Of Med
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- “Forty under 40â€Â
- Young Investigator Award
- Selected to be highlighted in the “Best of ASCO Program
- Early Career Achievement Award
- Susan G. Komen for the Cure: “Lifetime Achievement Awardâ€Â
- Career Development Award
- Paul Carbone, MD Fellowship Award
- Merit Award
Education
-
Indiana University School of Medicine
Drug Facts
| NPI NUMBER | 1811953433 | |
| NPPES Provider LastName | SCHNEIDER | |
| NPPES Provider FirstName | BRYAN | |
| NPPES Provider ZIPCode | 462025112 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 505.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 27.0 | |
| Percent Opioid Claims | 5.35 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811953433 |
| Last Name Of The Provider | SCHNEIDER |
| First Name Of The Provider | BRYAN |
| View All |
Similar Doctors
|
|
Dr. Shlomo M. Hellerstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Pablo M. Bedano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George W. Sledge Jr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lawrence H. Einhorn, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Tandra Anand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric H. Westin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Rushing, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sead Beganovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Strother, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniela E. Matei, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Fredrick C. Asirwa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura Tenner, MD |